-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Aurintricarboxylic acid
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/4431-00-9.gif)
| Category | Influenza Virus |
| CAS | 4431-00-9 |
| Description | Aurintricarboxylic acid acts as a histological dye and an insulin-like growth factor receptor 1 antagonist. |
Product Information
| Synonyms | 1,4-cyclohexadiene-1-carboxylic acid, 3-(bis(3-carboxy-4-hydroxyphenyl)methylen; aluminon free acid |
| IUPAC Name | 5-[(3-carboxy-4-hydroxyphenyl)-(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methyl]-2-hydroxybenzoic acid |
| Molecular Weight | 422.34 |
| Molecular Formula | C22H14O9 |
| Canonical SMILES | C1=CC(=C(C=C1C(=C2C=CC(=O)C(=C2)C(=O)O)C3=CC(=C(C=C3)O)C(=O)O)C(=O)O)O |
| InChI | InChI=1S/C22H14O9/c23-16-4-1-10(7-13(16)20(26)27)19(11-2-5-17(24)14(8-11)21(28)29)12-3-6-18(25)15(9-12)22(30)31/h1-9,23-24H,(H,26,27)(H,28,29)(H,30,31) |
| InChIKey | GIXWDMTZECRIJT-UHFFFAOYSA-N |
| Boiling Point | 759.6°C at 760 mmHg |
| Melting Point | 300°C |
| Flash Point | 427.1±29.4 °C |
| Purity | 95% |
| Density | 1.65 g/cm3 |
| Solubility | In Vitro: DMSO : 125 mg/mL(295.97 mM;Need ultrasonic) H2O : < 0.1 mg/mL (ultrasonic)(insoluble) In Vivo: 1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.92 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (4.92 mM); Clear solution |
| Appearance | deep red coarse crystalline powder |
| Storage | Powder: 3 years -20°C In solvent: 2 years -80°C |
| Complexity | 841 |
| Exact Mass | 422.06378202 |
| Index Of Refraction | 1.751 |
| In Vitro | Aurintricarboxylic acid weakly inhibits P2X2/3Rs, P2X2Rs, P2X4Rs or P2X7Rs. Aurintricarboxylic acid inhibits ATP-induced currents in a concentration dependent manner. Aurintricarboxylic acid can inhibit the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) and vaccinia virus. Aurintricarboxylic acid inhibits replication of influenza A and B viruses by inhibition of neuraminidase activities. Aurintricarboxylic acid inhibits TWEAK-Fn14-mediated NF-κB activation. Aurintricarboxylic acid (10 μM; 0.5-2 hours) suppresses TWEAK-Fn14-mediated NF-κB, Akt, and Src phosphorylation in GBM cells. Aurintricarboxylic acid represses TWEAK-stimulated glioma cell migration and invasion without causing cell cytotoxicity. Aurintricarboxylic acid cannot regulate loading of endogenous let-7 onto AGO2 inside cultured cells, whereas can inhibit RISC loading of exogenous siRNA. |
| PSA | 169.43000 |
| Target | P2X Receptor; Influenza Virus; Topoisomerase; MicroRNA; Apoptosis |
| Vapor Pressure | 0.0±2.7 mmHg at 25°C |
| XLogP3-AA | 4.3 |
